Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

A new study highlights that the experimental blood-thinner abelacimab significantly reduces bleeding risks in atrial fibrillation patients compared to standard treatments like rivaroxaban. In trial ...

The published results closely match the presentation. Find our full coverage below. PHILADELPHIA, PA—The novel factor XI inhibitor abelacimab, given subcutaneously once a month, is far less likely to ...

The median reduction in free factor XI levels was 99% and 97% with abelacimab at a dose of 150mg and 90mg, respectively, at 3 months. (HealthDay News) — Subcutaneous injection of abelacimab ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial.